Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry

Annals of Hematology

Volumn 94, Issue 4, 2015, Pages 651-661

  van der Poel, M W M ^a   Oerlemans, S ^b,c   Schouten, H C ^a   van de Poll Franse, L V ^b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b The Netherlands   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

Author keywords

Elderly; Multiple myeloma; Population based; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BODY IMAGE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER TRANSPLANTATION; COMORBIDITY; CONTROLLED STUDY; DETERIORATION; DYSPNEA; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUEST; EXPERIENCE; FEMALE; FINANCIAL DEFICIT; FUNCTIONAL STATUS; FUTUROLOGY; GERIATRIC PATIENT; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE QUESTIONNAIRE MULTIPLE MYELOMA MODULE 20; STEM CELL TRANSPLANTATION; COMPARATIVE STUDY; COST OF ILLNESS; HEALTH STATUS; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; REGISTER; SURVIVAL; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COST OF ILLNESS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; SURVIVAL ANALYSIS;

EID: 84925493002     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2264-0     Document Type: Article

References (38)

1. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/mulmy.html
2. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91–97
3. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883
4. Fermand JP, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol Off J Am Soc Clin Oncol 23:9227–9233
5. Qazilbash MH, Saliba RM, Hosing C et al (2007) Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39:279–283
6. Muta T, Miyamoto T, Fujisaki T et al (2013) Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Intern Med 52:63–70
7. Siegel DS, Desikan KR, Mehta J et al (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93:51–54
8. Palumbo A, Bringhen S, Petrucci MT et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104:3052–3057
9. Badros A, Barlogie B, Siegel E et al (2001) Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114:600–607
10. Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370:1209–1218
11. Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831
12. Fayers PM, Palumbo A, Hulin C et al (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239–1247
13. Wijermans P, Schaafsma M, Termorshuizen F et al (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol Off J Am Soc Clin Oncol 28:3160–3166
14. Hulin C, Facon T, Rodon P et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol Off J Am Soc Clin Oncol 27:3664–3670
15. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917
16. Mateos MV, Richardson PG, Schlag R et al (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol Off J Am Soc Clin Oncol 28:2259–2266
17. Palumbo A, Hajek R, Delforge M et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759–1769
18. Mols F, Oerlemans S, Vos AH et al (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311–319
19. Gulbrandsen N, Hjermstad MJ, Wisloff F, Nordic Myeloma Study G (2004) Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 72:172–180
20. Verelst SG, Termorshuizen F, Uyl-de Groot CA et al (2011) Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 90:1427–1439
21. Delforge M, Dhawan R, Robinson D Jr et al (2012) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 89:16–27
22. Dimopoulos MA, Delforge M, Hajek R et al (2013) Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 98:784–788
23. Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organisation, Geneva
24. van de Poll-Franse LV, Horevoorts N, van Eenbergen M et al (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47:2188–2194
25. van de Poll-Franse LV, Mols F, Gundy CM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47:667–675
26. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
27. Cocks K, Cohen D, Wisloff F et al (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670–1678
28. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49:156–163
29. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol Off J Am Soc Clin Oncol 29:89–96
30. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol Off J Am Soc Clin Oncol 16:139–144
31. Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33
32. van der Poel MW, Oerlemans S, Schouten HC, et al (2013) Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry. Annals of Hematology
33. Mols F, Thong MS, Vissers P, Nijsten T, van de Poll-Franse LV (2012) Socio-economic implications of cancer survivorship: results from the PROFILES registry. Eur J Cancer 48:2037–2042
34. Goodwin JA, Coleman EA, Sullivan E et al (2013) Personal financial effects of multiple myeloma and its treatment. Cancer Nurs 36:301–308
35. Kleber M, Ihorst G, Terhorst M et al (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1:e35
36. Kleber M, Ihorst G, Gross B et al (2013) Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 13:541–551
37. Dimopoulos MA, Palumbo A, Hajek R, et al (2013) Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >/= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia & Lymphoma
38. Gulbrandsen N, Wisloff F, Brinch L et al (2001) Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 18:65–77